BACKGROUND: Men and women with schizophrenia suffer not only from their illness but also from the side effects of their medications. OBJECTIVE: To review the toll of antipsychotic side effects specifically on women. STUDY DESIGN: A review of the literature in the PubMed database since 1990 using search terms: sex difference, antipsychotics, schizophrenia, pharmacokinetics, pharmacodynamics, and pharmacogenomics and retrieving additional publications from the reference lists of the original articles. RESULTS: Findings suggest that, because of differing pharmacokinetics, women are more vulnerable than men to weight gain secondary to antipsychotics and to the consequences (metabolic, cardiovascular, reproductive) of weight gain. They are also more vulnerable to hyperprolactinemia and QTc prolongation. CONCLUSIONS: Dosing guidelines need to be critically appraised. The greater toll of side effects in women may undermine adherence to prescribed treatments, add to the stigma that attaches to mental illness, and diminish the quality of women’s lives. Side effects increase the cost of mental illness and heighten the burden experienced by caregivers. They exacerbate morbidity and raise mortality rates. They affect the children of women treated with antipsychotic medication.
Ahn, J., Schatzkin, A., Lacey, J.V., Jr., Albanes, D., Ballard-Barbash, R., Adams, K.F., et al. (2007). Adiposity, adult weight change, and postmenopausal breast cancer risk. Archives of Internal Medicine, 167, 2091-2102.
2.
Aichhorn, W., Whitworth, A.B., Weiss, E.M., & Marksteiner, J. (2006). Second-generation antipsychotics: Is there evidence for sex differences in pharmacokinetic and adverse effect profiles? Drug Safety, 29, 587-598.
3.
Alvir, J.M.J., Lieberman, J.A., Safferman, A.Z., Schwimmer, J.L., & Schaaf, J.A. ( 1993). Clozapine-induced agranulocytosis: incidence and risk factors in the United States. New England Journal of Medicine , 329, 162-167.
4.
Alyea, R.A., Laurence, S.E., Kim, S.H., Katzenellenbogen, B.S., Katzenellenbogen, J.A., & Watson, C.S. ( 2008). The roles of membrane estrogen receptor subtypes in modulating dopamine transporters in PC-12 cells. Journal of Neuro-chemistry , 106, 1525-1533.
5.
Anderson, G.D. ( 2008). Gender differences in pharmacological response. International Review of Neurobiology, 83, 1-10.
Arnold, L.M., Strakowski, S.M., Schwiers, M.L., Amicone, J., Fleck, D.E.; Corey, K.B., et al. (2004). Sex, ethnicity, and antipsychotic medication use in patients with psychosis. Schizophrenia Research, 66, 169-175.
8.
Avery, C.L., Freedman, B.I., Kraja, A.T., Borecki, I.B., Miller, M.B., Pankow, J.S., et al. (2006). Genotype-by-sex interaction in the aetiology of type 2 diabetes mellitus: Support for sex-specific quantitative trait loci in Hypertension Genetic Epidemiology Network participants. Diabetologia, 49, 2329-2336.
9.
Bailey, M.S., & Curtis, A.B. ( 2002). The effects of hormones on arrhythmias in women. Current Women’s Health Reports, 2, 83-88.
10.
Barbui, C., Nosè, M., Bindman, J., Schene, A., Becker, T., Mazzi, M.A., et al. (2005). Sex differences in the subjective tolerability of antipsychotic drugs. Journal of Clinical Psychopharmacology , 25, 521-526.
11.
Basu, A., & Meltzer, H.Y. ( 2006). Differential trends in prevalence of diabetes and unrelated general medical illness for schizophrenia patients before and after the atypical antipsychotic era. Schizophrenia Research, 86, 99-109.
12.
Bergman, R.N., & Ader, M. ( 2005). Atypical antipsychotics and glucose homeostasis. Journal of Clinical Psychiatry, 66, 504-514.
13.
Björnsson, B., Orvar, K.B., Theodórs, A., & Kjeld, M. ( 2006). The relationship of gastrointestinal symptoms and menstrual cycle phase in young healthy women. Laeknabladid, 92, 677-682.
14.
Byerly, M., Suppes, T., Tran, Q.V., & Baker, R.A. ( 2007). Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: Recent developments and current perspectives. Journal of Clinical Psychopharmacology, 27, 639-661.
15.
Correll, C.U., Frederickson, A.M., Kane, J.M., & Manu, P. ( 2006). Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. Journal of Clinical Psychiatry, 67, 575-583.
16.
Correll, C.U., & Schenk, E.M. ( 2008). Tardive dyskinesia and new antipsychotics. Current Opinion in Psychiatry, 21, 151-156.
17.
Covell, N.H., Weissman, E.M., & Essock, S.M. ( 2004). Weight gain with clozapine compared to first generation antipsychotic medications. Schizophrenia Bulletin, 30, 229-240.
18.
Cubbon, R.M., Rajwani, A., Abbas, A., Gale, C.P., Grant, P.J., Wheatcroft, S.B., et al. (2007). Hyperglycaemia, in relation to sex, and mortality after acute coronary syndrome. European Journal of Cardiovascular Prevention & Rehabilitation, 14, 666-671.
19.
Dai, Z., Xu, Y.C., & Niu, L. ( 2007). Obesity and colorectal cancer risk: A meta-analysis of cohort studies. World Journal of Gastroenterology, 13, 4199-4206.
20.
Dalton, S.O., Johansen, C., Poulsen, A.H., Nørgaard, M., Sørensen, H.T., McLaughlin, J.K., et al. (2006). Cancer risk among users of neuroleptic medication: A population-based cohort study. British Journal of Cancer, 95, 934-939.
21.
De Bellis, A., Bizzarro, A., Pivonello, R., Lombardi, G., & Bellastella, A. (2005) Prolactin and autoimmunity . Pituitary, 8, 25-30.
22.
Ding, E.L., Song, Y., Malik, V.S., & Liu, S. ( 2006). Sex differences of endogenous sex hormones and risk of type 2 diabetes: A systematic review and meta-analysis. Journal of the American Medical Association, 295, 1288-1299.
23.
Drici, M.D., & Clément, N. (2001). Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome. Drug Safety, 24, 575-585.
24.
Eaton, W.W., Byrne, M., Ewald, H., Mors, O., Chen, C.Y., Agerbo, E., et al. (2006). Association of schizophrenia and autoimmune diseases: Linkage of Danish national registers. American Journal of Psychiatry, 163, 521-528.
25.
Eliassen, A.H., Colditz, G.A., Rosner, B., Willett, W.C., & Hankinson, S.E. (2006). Adult weight change and risk of postmenopausal breast cancer. Journal of the American Medical Association, 296, 193-201.
26.
Eliassen, A.H., Tworoger, S.S., & Hankinson, S.E. (2007). Reproductive factors and family history of breast cancer in relation to plasma prolactin levels in premenopausal and postmenopausal women. International Journal of Cancer, 120, 1536-1541.
27.
Flanagan, R.J. ( 2008). Side effects of clozapine and some other psychoactive drugs. Current Drug Safety, 3, 115-122.
28.
Friberg, E., Mantzoros, C.S., & Wolk, A. ( 2007). Diabetes and risk of endometrial cancer: A population-based prospective cohort study. Cancer Epidemiology: Biomarkers & Prevention, 16, 276-280.
29.
Gentile, S. ( 2006). Long-term treatment with atypical antipsychotics and the risk of weight gain: a literature analysis. Drug Safety , 29, 303-319.
30.
Goff, D.C., Sullivan, L.M., McEvoy, J.P., Meyer, J.M., Nasrallah, H.A., Daumit, G.L., et al. (2005). A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophrenia Research, 80, 45-53.
31.
Gregoor, J.G., van der Weide, J., Mulder, H.Cohen, D., van Megen, H.J., Egberts, A.C., et al. (2009). Polymorphisms of the LEP- and LEPR gene and obesity in patients using antipsychotic medication. Journal of Clinical Psychopharmacology, 29, 21-25.
32.
Guerin, A., Nisenbaum, R., & Ray, J.G. ( 2007). Use of maternal GHb concentration to estimate the risk of congenital anomalies in the offspring of women with prepregnancy diabetes . Diabetes Care, 30, 1920-1925.
33.
Hägg, S., Jönsson, A.K., & Spigset, O. ( 2009). Risk of venous thromboembolism due to antipsychotic drug therapy. Expert Opinion on Drug Safety, 8, 537-547.
34.
Hagström, B., Mattsson, B., Rost, I.M., & Gunnarsson, R.K. (2004). What happened to the prescriptions? A single, short, standardized telephone call may increase compliance. Family Practice, 21, 46-50.
35.
Hippisley-Cox, J., Vinogradova, Y., Coupland, C., & Parker, C. ( 2007). Risk of malignancy in patients with schizophrenia or bipolar disorder: Nested case-control study. Archives of General Psychiatry, 64, 1368-1376.
36.
Homel, P., Casey, D., & Allison, D.B. ( 2002). Changes in body mass index for individuals with and without schizophrenia, 1987-1996. Schizophrenia Research, 55, 277-284.
37.
Howard, L., Kirkwood, G., & Leese, M. ( 2007). Risk of hip fracture in patients with a history of schizophrenia . British Journal of Psychiatry, 190, 129-134.
38.
Howes, O.D., Wheeler, M.J., Pilowsky, L.S., Landau, S., Murray, R.M., & Smith, S. ( 2007). Sexual function and gonadal hormones in patients taking antipsychotic treatment for schizophrenia or schizoaffective disorder. Journal of Clinical Psychiatry, 68, 361-367.
39.
Hreiche, R., Morissette, P., & Turgeon, J. ( 2008). Drug-induced long QT syndrome in women: Review of current evidence and remaining gaps. Gender Medicine, 5, 124-135.
40.
Hummer, M., Malik, P., Gasser, R.W., Hofer, A., Kemmler, G., Moncayo Naveda, R.C., et al. (2005). Osteoporosis in patients with schizophrenia . American Journal of Psychiatry, 162, 162-167.
41.
Hung, O.R., Bands, C., Laney, G., Drover, D., Stevens, S., & MacSween, M. ( 1994). Drug allergies in the surgical population. Canadian Journal of Anaesthesia, 41, 1149-1155.
42.
Irigaray, P., Newby, J.A., Lacomme, S., & Belpomme, D. ( 2007). Overweight/obesity and cancer genesis: More than a biological link. Biomedical Pharmacotherapy, 61, 665-678.
43.
Jung, D.U., Conley, R.R., Kelly, D.L., Kim, D.W., Yoon, S.H., Jang, J.H., et al. (2006). Prevalence of bone mineral density loss in Korean patients with schizophrenia: a cross-sectional study. Journal of Clinical Psychiatry, 67, 1391-1396.
44.
Koga, M. ( 2003). Clinical factors related to gains in body mass index (BMI) among patients under long-term antipsychotic treatment. Seishin Shinkeigaku Zasshi, 105, 473-488.
45.
Kritzer, M.F., & Creutz, L.M. ( 2008). Region and sex differences in constituent dopamine neurons and immunoreactivity for intracellular estrogen and androgen receptors in mesocortical projections in rats. Journal of Neuroscience , 28, 9525-9535.
46.
Lacut, K., Mottier, D., & Pottier, P. ( 2008). Drugs and venous thromboembolism. Revue de Pneumologie Clinique, 64, 290-297.
47.
Larsson, S.C., & Wolk, A. ( 2007). Obesity and colon and rectal cancer risk: A meta-analysis of prospective studies. American Journal of Clinical Nutrition , 86, 556-565.
48.
Legato, M.J., Gelzer, A., Goland, R., Ebner, S.A., Rajan, S., Villagra, V., et al. (2006). Gender-specific care of the patient with diabetes: Review and recommendations. Gender Medicine, 3, 131-158.
49.
Lin, H.C., Hsiao, F.H., Pfeiffer, S., Hwang, Y.T., & Lee, H.C. ( 2008). An increased risk of stroke among young schizophrenia patients. Schizophrenia Research, 101, 234-241.
50.
Lipscombe, L.L., Goodwin, P.J., Zinman, B., McLaughlin, J.R., & Hux, J.E. ( 2006a). Diabetes mellitus and breast cancer: A retrospective population-based cohort study. Breast Cancer Research and Treatment, 98, 349-356.
51.
Lipscombe, L.L., Goodwin, P.J., Zinman, B., McLaughlin, J.R., & Hux, J.E. ( 2006b). Increased prevalence of prior breast cancer in women with newly diagnosed diabetes. Breast Cancer Research and Treatment, 98, 303-309.
52.
Liu-Seifert, H., Kinon, B.J., Tennant, C.J., Sniadecki, J., & Volavka, J. ( 2009). Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone. Neuropsychiatric Disease and Treatment, 5, 47-54.
53.
Mak, K.H., Ma, S., Heng, D., Tan, C.E., Tai, E.S., Topol, E.J., et al. (2007). Impact of sex, metabolic syndrome, and diabetes mellitus on cardiovascular events. American Journal of Cardiology, 100, 227-233.
54.
McCann, T.V., Clark, E., & Lu, S. ( 2009). Subjective side effects of antipsychotics and medication adherence in people with schizophrenia. Journal of Advanced Nursing, 65, 534-543.
55.
McCarthy, J.J. ( 2007). Gene by sex interaction in the etiology of coronary heart disease and the preceding metabolic syndrome. Nutrition, Metabolism, & Cardiovascular Diseases, 17, 153-161.
56.
Meaney, A.M., Smith, S., Howes, O.D., O’Brien, M., Murray, R.M., & O’Keane, V. (2004). Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. British Journal of Psychiatry, 184, 503-508.
57.
Mittendorfer, B. ( 2005). Insulin resistance: Sex matters. Current Opinion in Clinical Nutrition and Metabolic Care, 8, 367-372.
58.
Newcomer, J.W. ( 2005). Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review. Central Nervous System Drugs, 19(Suppl. 1), S1-S93.
59.
Nguyen, D., Brakoulias, V., & Boyce, P. ( 2009). An evaluation of monitoring practices in patients on second generation antipsychotics. Australasian Psychiatry , 17, 295-299.
60.
Nguyen, H.N., & Lalonde, P. ( 2003). Clozapine and pregnancy. Encephale, 29, 119-124.
61.
Novak, L., & Svab, V. ( 2009). Antipsychotics side effects’ influence on stigma of mental illness: Focus group study results. Psychiatria Danubina, 21, 99-102.
62.
Orbach, H., & Shoenfeld, Y. ( 2007). Hyperprolactinemia and autoimmune diseases. Autoimmunity Review, 6, 537-542.
63.
Parsons, B., Allison, D.B., Loebel, A., Williams, K., Giller, E., Romano, S., et al. (2009). Weight effects associated with antipsychotics: A comprehensive database analysis. Schizophrenia Research, 110, 103-110.
64.
Pischon, T., Lahmann, P.H., Boeing, H., Friedenreich, C., Norat, T., Tjønneland, A., et al. (2006). Body size and risk of colon and rectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). Journal of the National Cancer Institute, 98, 920-931.
65.
Rademaker, M. ( 2001). Do women have more adverse drug reactions? American Journal of Clinical Dermatology, 2, 349-351.
66.
Ramaswamy, K., Masand, P.S., & Nasrallah, H.A. (2006). Do certain atypical antipsychotics increase the risk of diabetes? A critical review of 17 pharmacoepidemiologic studies. Annals of Clinical Psychiatry, 18, 183-194.
67.
Rankinen, T., Zuberi, A., Chagnon, Y.C., Weisnagel, S.J., Argyropoulos, G., Walts, B., et al. (2006). The human obesity gene map: The 2005 update . Obesity, 14, 529-644.
68.
Ray, J.G., Wyatt, P.R., Vermeulen, M.J., Meier, C., & Cole, D.E. ( 2005). Greater maternal weight and the ongoing risk of neural tube defects after folic acid flour fortification. Obstetrics & Gynecology, 105, 261-265.
69.
Regitz-Zagrosek, V., Lehmkuhl, E., & Weickert, M.O. (2006). Gender differences in the metabolic syndrome and their role for cardiovascular disease. Clinical Research in Cardiology, 95, 136-147.
70.
Riecher-Rössler, A., Schmid, C., Bleuer, S., & Birkhäuser, M. (2009). Antipsychotics and hyperpolactinaemia: Pathophysiology, clinical relevance, diagnosis and therapy. Neuropsychiatrie, 23, 71-83.
71.
Rostami-Hodjegan, A., Amin, A.M., Spencer, E.P., Lennard, M.S., Tucker, G.T., & Flanagan, R.J. (2004). Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: A predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. Journal of Clinical Psychopharmacology , 24, 70-78.
72.
Schwartz, J.B. ( 2003). The influence of sex on pharmacokinetics. Clinical Pharmacokinetics, 42, 107-121.
73.
Shi, Y., Guo, M., Yan, J., Sun, W., Zhang, X., Geng, L., et al. (2007). Analysis of clinical characteristics in large-scale Chinese women with polycystic ovary syndrome. Neuroendocrinology Letters, 28, 807-810.
74.
Tarricone, I., Casoria, M., Gozzi, B.F., Grieco, D., Menchetti, M., Serretti, A., et al. (2006). Metabolic risk factor profile associated with use of second generation antipsychotics: A cross sectional study in a community mental health centre. BMC Psychiatry, 6, 11.
75.
Tran, E., Rouillon, F., Loze, J.Y., Casadebaig, F., Philippe, A., Vitry, F., et al. (2009) Cancer mortality in patients with schizophrenia: An 11-year prospective cohort study. Cancer, 115, 3555-3562
76.
van Os, J., Walsh, E., van Horn, E., Tattan, T., Bale, R., & Thompson, S.G. (1999). Tardive dyskinesia in psychosis: Are women really more at risk?Acta Psychiatrica Scandinavica , 99, 288-293.
77.
Vestergaard, P., Rejnmark, L., & Mosekilde, L. ( 2006). Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture. Osteoporosis International, 17, 807-816.
78.
Waller, D.K., Shaw, G.M., Rasmussen, S.A., Hobbs, C.A., Canfield, M.A., Siega-Riz, A.M., et al. (2007). National Birth Defects Prevention Study. Prepregnancy obesity as a risk factor for structural birth defects. Archives of Pediatric & Adolescent Medicine, 161,745-750.
79.
Wang, J.S., Zhu, H.J., Markowitz, J.S., Donovan, J.L., Yuan, H.J., & Devane, C.L. ( 2008). Antipsychotic drugs inhibit the function of breast cancer resistance protein. Basic & Clinical Pharmacology & Toxicology, 103, 336-341.
80.
Wang, P.S., Walker, A.M., Tsuang, M.T., Orav, E.J., Glynn, R.J., Levin, R., et al. (2002). Dopamine antagonists and the development of breast cancer. Archives of General Psychiatry, 59, 1147-1154.
81.
Weiss, U., Marksteiner, J., Kemmler, G., Saria, A., & Aichhorn, W. ( 2005). Effects of age and sex on olanzapine plasma concentrations . Journal of Clinical Psychopharmacology, 25, 570-574.
82.
White, R.H. ( 2003). The epidemiology of venous thromboembolism. Circulation, 107, 1-4.
83.
Yassa, R., & Jeste, D.V. ( 1992). Gender differences in tardive dyskinesia: A critical review of the literature. Schizophrenia Bulletin, 18, 701-715.
84.
Zornberg, G.L., & Jick, H. ( 2000). Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: A case-control study. Lancet, 356, 1219-1223.
